Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Bohui Innovation Biotechnology Group Co., Ltd. (300318.SZ)
Beijing, CN
Beijing Bohui Innovation Biotechnology Group Co., Ltd. is a Chinese enterprise that manages the full spectrum of diagnostic product operations, from initial research and development through manufacturing, sales, and post-sale support. Their offerings include a variety of diagnostic tools such as the GenPlex microfluidic automated system for nucleic acid detection, immunofluorescence detection solutions, and products for analyzing human trace elements. Additionally, the company provides advanced chemical analysis instrumentation, featuring atomic fluorescence spectrometers, photometers, mass spectrometers, chip ion sources, microfluidic flow chemical analysis systems, and ICP spectroscopy equipment, along with vital consumables for life sciences. Founded in 2001, the company is headquartered in Beijing, China. It adopted its current name, Beijing Bohui Innovation Biotechnology Group Co., Ltd., in August 2021, having previously been known as Beijing Bohui Innovation Biotechnology Co., Ltd.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.53% | +2.38% | -7.13% | -15.54% | -2.78% | -10.69% | -5.41% | -3.28% | -27.93% | -43.97% | +90.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-3.8% Q1'26: -5.8% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-1,073.5% Q1'26: -78.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-35.5% Q1'26: -34.4% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-5.4% Q1'26: +0.8% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%-1.4% Q1'26: +0.2% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.2% ★ Q1'26: +0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×16.32× Q1'26: 162.15× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
|---|---|---|
| Revenue |
622.09M
est: 485.69M (+28.1%)
|
628.34M
est: 594.33M (+5.7%)
|
| EBITDA |
208.98M
est: 8.99M (+2,225.8%)
|
126.33M
est: 10.99M (+1,049.0%)
|
| EBIT |
141.42M
est: -57.38M (+346.5%)
|
53.06M
est: -70.22M (+175.6%)
|
| Net Income |
69.44M
|
2.54M
|
| SGA |
199.54M
est: 92.52M (+115.7%)
|
210.20M
est: 113.21M (+85.7%)
|
| EPS |
0.08
|
0.00
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 76.7K | 0.65% |
| 2 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 172.7K | 0.06% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 39.8K | 0.29% |
| 4 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 12.6K | 0.26% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 5.6K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 622.4K | 0.06% |
| 7 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 16.1K | 0.39% |
| 8 | Vanguard ESG International Stock ETF VSGX | 0.00% | 10.7K | 0.10% |
| 9 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 16.7K | 0.28% |
| 10 | Vanguard Total International Stock ETF VXUS | 0.00% | 773.1K | 0.05% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haifeng Dong | Deputy GM, Secretary & Director | — | male |
| Jia Liu | Financial Director | — | female |
| Wei Na Gong | Accounting Supervisor | — | — |
| Zhiwei Shen | Chairman of the Board & GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300318.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
